Drug Name |
Tranexamic acid |
Drug ID |
BADD_D02261 |
Description |
Tranexamic acid is a synthetic derivative of [lysine] used as an antifibrinolytic in the treatment and prevention of major bleeding. It possesses a similar mechanism of action to [aminocaproic acid] but is approximately 10-fold more potent.[L31883]
It was first patented in 1957[A230108] and received its initial US approval in 1986.[L31858] |
Indications and Usage |
Taken orally, tranexamic acid is indicated for the treatment of hereditary angioedema,[L31883] cyclic heavy menstrual bleeding in premenopausal females,[L31858] and other instances of significant bleeding in the context of hyperfibrinolysis.[L31883] Given intravenously, tranexamic acid is indicated for short-term use (2-8 days) in patients with hemophilia to prevent or reduce bleeding following tooth extraction.[L31853] |
Marketing Status |
approved |
ATC Code |
B02AA02 |
DrugBank ID |
DB00302
|
KEGG ID |
D01136
|
MeSH ID |
D014148
|
PubChem ID |
5526
|
TTD Drug ID |
D05HXX
|
NDC Product Code |
51927-0022; 73309-178; 42571-189; 50268-772; 69918-301; 70771-1085; 0591-3720; 49452-7876; 51552-0513; 81999-0001; 82920-038; 70121-1398; 23155-524; 43066-008; 55150-188; 63629-8838; 67850-041; 68083-160; 71335-1981; 60505-6169; 65145-106; 0517-0960; 81284-611; 12079-2001; 62991-3131; 82920-045; 51662-1532; 63629-8599; 67457-197; 70860-400; 70860-407; 71335-1957; 81284-612; 14537-115; 65388-0156; 61990-0611; 67850-042; 38779-3211; 57218-951; 25021-415; 42571-314; 50090-5072; 63323-563; 68382-891; 72611-760; 12848-1004; 0013-1114; 69918-300; 49452-7877; 71052-166; 23155-166; 51754-0108; 62559-265; 72485-107; 38779-2794; 39822-1000 |
UNII |
6T84R30KC1
|
Synonyms |
Tranexamic Acid | AMCHA | trans-4-(Aminomethyl)cyclohexanecarboxylic Acid | t-AMCHA | AMCA | Anvitoff | Cyklokapron | Ugurol | KABI 2161 | Spotof | Transamin | Amchafibrin | Exacyl |